Alvotech combines a clear strategic focus on biosimilars with an advanced, efficient manufacturing platform and growing commercial momentum. Revenue has ramped sharply, gross and operating margins have improved, and liquidity has strengthened. The company’s product portfolio includes differentiated, interchangeable biosimilars to major biologics, supported by strong partnerships and a broad pipeline targeting multiple large therapeutic areas.

The main concerns are financial and structural. The company remains loss-making, with heavily negative free cash flow, rising debt, and deeply negative equity, all of which point to ongoing dependence on capital markets. Competitive and regulatory risks in the biosimilar space are high, and pricing pressure could limit margins even as volumes grow. Reliance on a few key products and partners heightens execution and concentration risks, especially if launch timelines slip or competitors gain advantage.

The outlook is tied to whether Alvotech can translate its recent commercial inflection and technological strengths into a sustainably profitable, cash-generative business before balance sheet pressures become acute. If the company continues to scale revenues, maintain healthy operational margins, and successfully launch pipeline products on schedule, its financial profile could improve meaningfully over time. Until that transition is clearer, the story remains one of promising strategic positioning and innovation set against significant financial and execution uncertainty.